Bill & Melinda Gates Foundation

BioSurfaces is a provider of medical care services intended to be offered by augmenting existing and emerging medical approaches with nanotechnology. The company's services applies room-temperature electrospinning process to allow drug loading into each fiber, providing a reservoir for sustained drug release at the implant site, enabling customers to make devices and coatings as thin as 10um which can treat diseases at site.

Freya Biosciences is a clinical-stage company focused on women's health, with operations in Copenhagen and Boston. It specializes in developing microbial immunotherapies aimed at addressing significant unmet medical needs across various conditions. The company utilizes a proprietary platform to engineer and manufacture live microbes, ensuring their safety and efficacy for human use. Through this innovative approach, Freya Biosciences seeks to create new treatment options for a range of diseases, striving to make a meaningful impact in the healthcare sector.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.

ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteins to be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent.

Surf Bio is a preclinical biopharmaceutical company leveraging a breakthrough next-generation surfactant to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas.

Owlstone Medical Ltd is a diagnostics company based in Cambridge, United Kingdom, specializing in non-invasive breath-based diagnostic tools aimed at the early detection of diseases, including cancer and respiratory conditions. The company develops a range of innovative products, including its Breath Biopsy platform, which utilizes advanced technology to identify volatile organic compounds in breath samples. Its offerings include FAIMS technology for medical applications, Lonestar for disease biomarker detection, and ReCIVA breath samplers for in vitro analysis. Owlstone Medical's technology has significant applications in various medical fields, such as lung cancer, bowel cancer, and gastrointestinal disorders. The company is also exploring the development of a portable hand-held device that promises high sensitivity and selectivity for chemical detection, with potential applications across multiple markets, including military and industrial sectors. Owlstone Medical aims to become a leader in non-invasive diagnostics, with ongoing collaborations and trials, including contracts with the UK National Health Service for lung cancer screening initiatives.

Owlstone Medical Ltd is a diagnostics company based in Cambridge, United Kingdom, specializing in non-invasive breath-based diagnostic tools aimed at the early detection of diseases, including cancer and respiratory conditions. The company develops a range of innovative products, including its Breath Biopsy platform, which utilizes advanced technology to identify volatile organic compounds in breath samples. Its offerings include FAIMS technology for medical applications, Lonestar for disease biomarker detection, and ReCIVA breath samplers for in vitro analysis. Owlstone Medical's technology has significant applications in various medical fields, such as lung cancer, bowel cancer, and gastrointestinal disorders. The company is also exploring the development of a portable hand-held device that promises high sensitivity and selectivity for chemical detection, with potential applications across multiple markets, including military and industrial sectors. Owlstone Medical aims to become a leader in non-invasive diagnostics, with ongoing collaborations and trials, including contracts with the UK National Health Service for lung cancer screening initiatives.

Corner Therapeutics is a biotechnology research company focused on immunotherapy. It specializes in developing technologies that stimulate exceptional memory T cells to achieve lifelong immunity. The company utilizes a versatile dendritic cell hyperactivation platform that induces strong T-cell responses, aiming to provide robust and durable immunity against a wide range of cancers and infectious diseases. By enhancing T-cell activation, Corner Therapeutics seeks to enable healthcare providers to promote lasting immunity and optimize immune regulation.

PhaSER Biomedical is Exploiting the 8HUM mouse, a unique mouse model with multiple utilities in drug discovery, and development.

Sail Biomedicines is a flagship pioneering company that is developing tomorrow's medicines today using life's language. Sail's platform combines first-in-class translatable circular RNA technology (Endless RNATM or eRNA) with unique programmable nanoparticles based on natural components to thoroughly program medications for the first time.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Philips is a global technology company that specializes in healthcare, consumer lifestyle, and lighting products, solutions, and services. The company provides a wide range of offerings, including healthcare solutions, professional lighting products, oral healthcare items, and innovative display technologies. For consumers, Philips offers electronic products in categories such as sound and vision, personal care, mother and child care, housewares, and lighting. The company's commitment to improving health and well-being is evident in its focus on meaningful innovation and its efforts to address healthcare inequalities through initiatives like the Philips Foundation, which aims to enhance access to quality healthcare for disadvantaged communities.

AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.

EHA Clinics is dedicated to providing accessible, effective, and affordable healthcare services. The organization offers a comprehensive healthcare network that includes routine medical care, laboratory services, pharmacy, optometry, dental care, urgent care, and specialist consultations. EHA Clinics ensures that members have round-the-clock access to healthcare through various channels, including physical locations, telehealth virtual visits, and home care services. By leveraging technology and a skilled team, EHA Clinics aims to enhance the healthcare experience, improve patient outcomes, and offer competitive pricing for individual, family, and business members.

Latham BioPharm Group (LBG) provides the insight, knowledge, and network to unite teams and technologies in the Life Sciences. They provide the depth of expertise necessary to advance your programs, by providing a range of life science services including business development, program management, CMC, quality, regulatory, and strategic consulting with proven experience in biodefense/pandemic response and strategic product development. Our team has an average of over 20 years’ experience and many have served as senior executives at companies ranging from start-ups to Fortune 200 companies. A number of us have also held senior level positions within the US government. For over twenty years, they have helped clients identify, evaluate, fund, manage, and monetize opportunities in a wide variety of business segments, generating over $1 billion in government funding and over $100 million in licensing fees and investments. On the front end, they assist clients in evaluating critical business decisions and connecting with the target markets to assess opportunities with our Strategy and Portfolio Analysis, Market Research, and Commercial and Government Asset Analysis offerings. They then assist in finding and securing funding through our Business Development and Non-Dilutive Funding Services. Once funded, they drive successful advancement to a targeted value-inflection point through our Program Management and Product Development Team services.

Aegis Life is a biotechnology company focused on advancing nucleic acid delivery technology, specifically through its proprietary platform known as fusogenix PLV. This technology, developed over two decades, is designed to facilitate the rapid development and commercialization of vaccines and therapeutics aimed at preventing and treating infectious diseases. Aegis Life's innovative approach supports the pharmaceutical industry in accelerating the discovery, clinical development, and manufacturing processes for vaccines and treatments, particularly in response to emerging health threats such as COVID-19.

Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.

The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, that focuses on developing therapeutic products aimed at treating and preventing serious infectious diseases. The company is working on several key therapies, including VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for human immunodeficiency virus, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established collaborations and agreements with various organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, Brii Biosciences, Alnylam Pharmaceuticals, and others, to further its research and development efforts. Additionally, it has a manufacturing agreement with Samsung Biologics for producing antibodies related to COVID-19 treatments. Founded in 2016, Vir Biotechnology aims to leverage its innovative platforms to potentially eradicate diseases like hepatitis B, influenza A, HIV, and tuberculosis.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Osivax is a company focused on developing immunotherapy vaccines aimed at treating infectious diseases. Its innovative vaccines enhance the uptake into dendritic cells and boost the immunogenicity of natural proteins, which triggers a more effective immune response, particularly through significant CD8 T cell activation. This technology is designed to serve as a universal vaccine, targeting not only existing but also emerging coronavirus infections, as well as other globally impactful infectious diseases. In addition to infectious diseases, Osivax's vaccines also support cancer treatment, providing medical practitioners with advanced tools to treat a range of serious health conditions effectively.

SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines using a proprietary technology known as molecular superglue. This platform allows for the rapid creation of bonding vaccines by attaching antigens to viruses and other particles, enhancing the vaccine development process. By leveraging this unique approach, SpyBiotech aims to provide medical institutions and research centers with more effective vaccines that can be developed in a shorter timeframe, ultimately improving immunity against various diseases, including bacterial infections.

DelSiTech, Ltd. is a technology specialist based in Turku, Finland, focused on developing and licensing long-term controlled drug delivery systems. Established in 2001, the company specializes in biodegradable silica-based implants and injectable formulations for the controlled release of small molecular drugs, biopharmaceuticals, and viral vectors. DelSiTech's innovative technology embeds active ingredients within a silica matrix, facilitating parenteral and local administration through injectable depot, implant, and eye drop dosage forms. By providing expertise in controlled release products, DelSiTech aims to address various drug-related challenges and support clients in the development of supergeneric solutions.

MIP Discovery is a technology leader specializing in the development of molecularly imprinted polymers (MIPs) and nanoMIPs, which are plastic antibodies designed to address the limitations of traditional MIP manufacturing methods. The company's innovations feature polymers and antibodies that incorporate a single binding site for specific targets, allowing them to be effectively fused to solid substrates, such as sensor surfaces. This capability provides hospitals with highly effective reagents suitable for a variety of applications, including point-of-care diagnostics and field-based testing, thereby enhancing the efficiency and accuracy of medical testing.

VisualDx is a clinical decision support system that aims to improve diagnostic accuracy and patient safety in healthcare settings. By integrating a curated medical image library with a robust search engine, it provides clinicians with patient-specific answers swiftly, facilitating informed therapeutic decisions. The platform encompasses high-quality images covering a range of both pediatric and adult medical conditions. Used by over 2,300 hospitals, clinics, and medical schools globally, VisualDx enhances point-of-care decisions and fosters better patient engagement, enabling healthcare providers to deliver timely and effective care.

Aspen Pharmacare Holdings Limited is a global pharmaceutical company headquartered in Durban, South Africa, specializing in the manufacture and supply of both branded and generic pharmaceutical products. It operates primarily through two segments: Commercial Pharmaceuticals and Manufacturing. Aspen offers a diverse range of products, including general anaesthetics, muscle relaxants, cytotoxic medications, and injectable anticoagulants, particularly focusing on low molecular weight heparins and Xa inhibitors. The company also engages in the contract production and supply of active pharmaceutical ingredients (APIs) and finished pharmaceuticals for third parties. With a presence in over 150 countries, Aspen serves various markets, including South Africa, Australia, and several nations across Europe and Asia. Its extensive capabilities in manufacturing encompass both API and finished dosage forms, addressing a wide array of therapeutic needs. Founded in 1850, Aspen has expanded its reach significantly through strategic acquisitions, enhancing its footprint in emerging markets and contributing to a diverse portfolio of healthcare solutions.

Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, specializing in DNA therapies and technology. Founded in 2007, it has developed the proTL synthetic DNA platform, which allows for the production of doggybone closed linear DNA without the need for bacterial fermentation. This innovative approach supports various applications, including veterinary vaccines, monoclonal antibodies, cancer and gene therapies, allergy treatments, RNA interference therapies, and stem cell reprogramming. The company boasts a skilled scientific and drug development team, led by founder and CEO Jonny Ohlson, and includes experienced professionals such as Clive Dix and John Tite. Touchlight has established partnerships with several leading academic institutions, including Imperial College London and the University of Pennsylvania, to advance its research and development efforts. The company has successfully patented its synthetic DNA platform and demonstrated therapeutic proof-of-principle through collaboration with these academic partners.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

SwipeRx is a digital platform designed to enhance the operations of pharmacies by connecting pharmaceutical manufacturers, pharmacies, and patients. It offers a range of services, including specialized healthcare logistics, negotiated pricing, and financing solutions, creating a robust network for pharmacy purchasing. The platform generates insights that facilitate collaboration with pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and enhances daily operational efficiencies. By providing real-time access to patient and sell-out data, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

Cardea Bio, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing bioelectronics for research and diagnostics. Established in 2013, Cardea utilizes proprietary graphene-based digital biosensors to create advanced biosensor hardware, software, and molecular infrastructure, enabling precision healthcare through improved diagnostic capabilities. The company's product offerings include the AGILE R100, an innovative assay for drug discovery, and the AGILE R200, an automated high-throughput screening solution. Cardea's biosensors convert biomolecular interactions into digital data, allowing for real-time biological signal analysis and access to streaming multi-omics data. Their solutions cater to various applications in life sciences and healthcare, such as small molecule validation, antibody characterization, and biomolecular analysis.

Yemaachi Biotechnology is focused on advancing the diagnosis and treatment of cancer through innovative therapeutic technologies. The company employs immunogenomics, bioinformatics, and artificial intelligence to enhance the development of effective cancer detection and treatment strategies. By leveraging these advanced methodologies, Yemaachi aims to lower the economic burden of cancer and improve patient outcomes through more accurate and efficient therapeutic solutions.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in San Jose, California, that specializes in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to address life-threatening infections. The company’s lead product candidate, AR-301, is currently undergoing Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis is advancing several other candidates, including AR-105, a fully human IgG1 mAb in Phase II trials targeting the gram-negative bacterium P. aeruginosa, and AR-101, which is also in Phase II trials for hospital-acquired pneumonia caused by the same pathogen. Other projects in development include AR-401, AR-201, and AR-501, which target various serious infections. Aridis employs proprietary technology platforms to identify and manufacture potent mAbs derived from patients who have successfully overcome infections, enabling the production of therapeutics that are optimized for efficacy without requiring genetic modification. Founded in 2003, Aridis Pharmaceuticals is committed to providing innovative solutions for critical infections.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Elarex is a Canadian healthcare technology company commercializing its proprietary PT120 formulation technology which has proven to stabilize biologicals (including live vaccines!) so that they are as effective when stored at 40C as if they had been stored at -80C.

Providence Therapeutics is a biotechnology company that develops a personalized mRNA cancer vaccine designed to treat advanced ovarian cancer. The company's vaccine identifies tumor mutations and elicits an immune response against the tumor cells, enabling users to treat themselves and live life to the fullest. It aims to provide safe and effective medicines for people suffering from diseases with unmet medical needs. Scott Leary, Eric Marcusson, and Bradley Sorenson established the company in Toronto, Ontario in 2015.

Philips is a global technology company that specializes in healthcare, consumer lifestyle, and lighting products, solutions, and services. The company provides a wide range of offerings, including healthcare solutions, professional lighting products, oral healthcare items, and innovative display technologies. For consumers, Philips offers electronic products in categories such as sound and vision, personal care, mother and child care, housewares, and lighting. The company's commitment to improving health and well-being is evident in its focus on meaningful innovation and its efforts to address healthcare inequalities through initiatives like the Philips Foundation, which aims to enhance access to quality healthcare for disadvantaged communities.

Inventprise is a biotechnology company based in Redmond, Washington, focused on developing vaccines to combat infectious diseases. Established in 2012, the company is known for its 25-valent pneumococcal conjugate vaccine (PCV), which is supported by significant funding from the Bill and Melinda Gates Foundation, exceeding $100 million. This vaccine is specifically designed for large-scale distribution in low- and middle-income countries. In addition to vaccine development, Inventprise offers comprehensive contract manufacturing and development services, including quality control assays, batch records, and training. The company also operates a fully equipped quality control laboratory that conducts testing for identity, potency, purity, and stability, thereby assisting clients in addressing health disparities and promoting public health.

Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders. Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.3 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the sublingual formulations. The New Drug Application (NDA) was submitted to the FDA in October, 2012 seeking approval for treatment of opioid dependence. In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties. Probuphine is the first product to utilize ProNeura™, a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, round-the-clock blood levels of a drug can benefit the patient and improve medical outcomes. Finally, Titan is also entitled to royalty revenue of 8-10% of net sales of Fanapt® (iloperidone), an atypical antipsychotic compound being marketed in the U.S. for the treatment of schizophrenia by Novartis Pharma AG (“Novartis”) under a sub-license agreement based on a licensed U.S. patent that expires in October 2016 (does not include a possible six month pediatric extension). Substantially all of this future royalty revenue has been sold to Deerfield Management (“Deerfield”), a healthcare investment fund, in exchange for cash and debt considerations which have been used to advance the development of Probuphine and for general corporate purposes.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

Dynavax Technologies Corporation is a biopharmaceutical company based in Emeryville, California, focused on developing and commercializing innovative vaccines. The company's primary product, HEPLISAV-B, is an approved hepatitis B vaccine designed to prevent infection from all known subtypes of the virus in adults aged 18 and older. Dynavax is also advancing its proprietary CpG 1018 adjuvant to enhance vaccine efficacy and is engaged in various collaborations aimed at developing adjuvanted vaccines for COVID-19, pertussis, and universal influenza. In addition to its commercial efforts, Dynavax is involved in research partnerships with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations to create new vaccine candidates. The company was originally founded in 1996 as Double Helix Corporation and rebranded to its current name in September 1996.

E25Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing rapid diagnostic tests for epidemic fever viruses, including dengue, chikungunya, and Zika. Founded in 2018, the company specializes in paper-based diagnostic systems that enable swift detection of viral antigens produced during infections. Its innovative platform allows for real-time data reporting through a mobile application, which captures results along with information on test timing and location. This approach aims to facilitate epidemiologic predictions and disease mapping, ultimately assisting governments and health organizations in managing outbreaks effectively and preventing public health crises. E25Bio's solutions are designed to provide affordable and timely diagnostics at the point of care.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, focused on enhancing global health outcomes through early disease detection. The company has developed a proprietary technology platform that enables the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This platform facilitates the analysis of native-state biomarkers and nanoparticles, supporting multiomics applications. Biological Dynamics specializes in cancer detection and offers a range of services, including the TR(ACE) Assay for monitoring treatment responses and tumor burdens, as well as liquid biopsy testing for personalized medicine. Additionally, the company provides clinical laboratory services, including molecular and next-generation sequencing, and has programs aimed at drug development in areas such as Alzheimer's disease. Founded in 2008, Biological Dynamics is committed to utilizing machine learning and its advanced technology to address various health challenges, including autoimmune diseases, transplant rejection, and traumatic brain injury.

VisualDx is a clinical decision support system that aims to improve diagnostic accuracy and patient safety in healthcare settings. By integrating a curated medical image library with a robust search engine, it provides clinicians with patient-specific answers swiftly, facilitating informed therapeutic decisions. The platform encompasses high-quality images covering a range of both pediatric and adult medical conditions. Used by over 2,300 hospitals, clinics, and medical schools globally, VisualDx enhances point-of-care decisions and fosters better patient engagement, enabling healthcare providers to deliver timely and effective care.

Almac Group is a contract development and manufacturing organization that provides a comprehensive array of services to pharmaceutical and biotech companies worldwide. Established over 40 years ago and privately owned, the company offers research and development, biomarker discovery, active pharmaceutical ingredient (API) manufacturing, formulation development, clinical trial supply, and commercial-scale manufacturing, among other services. With its headquarters in Craigavon, Northern Ireland, Almac has expanded its operations to various locations, including the UK, Ireland, the US, and Asia. The company employs over 4,500 staff and is committed to continuous investment in its offerings, which encompass biomarker and companion diagnostics, clinical trial data management, and biocatalytic API manufacture. Additionally, Almac Discovery, a division of the group, focuses on innovative oncology research and the early-stage development of novel cancer treatments in partnership with pharmaceutical companies.

Landcent accelerates the fight against global infectious diseases, by developing & delivering affordable, sustainable solutions, that are safe to use at scale.

MedinCell is an injectable slow-release drug specialist company.

RJH Biosciences is a biotechnology company specializing in the development of transfection reagents and delivery systems designed to transport various types of nucleic acids into human cells and cell lines. The company emphasizes innovative solutions for addressing blood cancers and modifying immune cells, thereby enhancing the therapeutic potential of nucleic acids in medical applications. RJH Biosciences distributes its products through its website and is also engaged in projects aimed at developing new medical treatments.

One.bio is a biotechnology spinout from UC Davis that specializes in developing naturally-derived oligosaccharides for applications in food, agriculture, and biopharmaceuticals. Utilizing proprietary technology, the company creates innovative ingredients aimed at modulating the microbiome and enhancing immune function. This focus allows One.bio to provide clients with access to novel prebiotics and therapies that support both human and animal health. By unlocking the benefits of nutrition, One.bio aims to contribute to improved longevity and overall well-being.

Enesi Pharma is an innovative pharmaceutical company developing novel products with potential to transform performance and delivery of vaccines and make a material impact on global healthcare. The company’s primary focus is the development of novel solid dose vaccines against a range of infectious and other select diseases, working in partnership with global companies, government agencies and non-governmental organizations.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, founded in 2016. It connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its services. Users can engage with medical professionals via video calls, voice calls, and chat, making healthcare more accessible. The platform also allows patients to order laboratory tests that can be conducted at home. Additionally, HaloDoc helps users locate the nearest hospitals and clinics, streamlining the process of obtaining medical advice and services in real-time.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, focused on enhancing global health outcomes through early disease detection. The company has developed a proprietary technology platform that enables the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This platform facilitates the analysis of native-state biomarkers and nanoparticles, supporting multiomics applications. Biological Dynamics specializes in cancer detection and offers a range of services, including the TR(ACE) Assay for monitoring treatment responses and tumor burdens, as well as liquid biopsy testing for personalized medicine. Additionally, the company provides clinical laboratory services, including molecular and next-generation sequencing, and has programs aimed at drug development in areas such as Alzheimer's disease. Founded in 2008, Biological Dynamics is committed to utilizing machine learning and its advanced technology to address various health challenges, including autoimmune diseases, transplant rejection, and traumatic brain injury.

Univercells is a provider of biomanufacturing solutions focused on making biologics, including vaccines and therapeutics, more accessible and affordable. The company offers innovative technologies designed to reduce manufacturing costs significantly, achieving up to 90% savings on the cost of goods and over 75% in capital investment. Their approach utilizes single-use technologies and integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode. Univercells also provides a range of biomanufacturing services, including scale-X hydro, scale-X carbo, and NevoLine, along with integrated support such as equipment confirmation, facility design, and bioprocess excellence. This comprehensive offering aids cell and gene therapy manufacturers in scaling their operations from research and development to commercial production, ultimately addressing global health challenges.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Lyell Immunopharma is a clinical-stage company focused on developing innovative T cell therapies for patients with solid tumors. The company aims to overcome major challenges in adoptive T cell therapy, such as T cell exhaustion and the loss of durable stemness, which affects the efficacy of treatment. To achieve this, Lyell employs proprietary ex vivo genetic and epigenetic reprogramming technologies, known as Gen-R and Epi-R, to enhance T cell functionality. The company's product pipeline includes several candidates, such as LYL797, LYL119, and LYL845, which are designed to provide improved and lasting therapeutic outcomes for patients.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Evolve Biosystems, Inc. is a biotechnology company based in Davis, California, focused on developing and marketing probiotic-based biotherapeutics aimed at establishing, restoring, and maintaining a healthy human microbiome. The company specializes in addressing gut dysbiosis across the human life cycle, particularly in newborns during their first six months of life. Evolve Biosystems utilizes a platform that combines specific probiotic bacteria with prebiotic oligosaccharides to create effective delivery systems. Their products include consumer-directed solutions for home use as well as specialized formulations for neonatal intensive care units. In addition to human health, the company also applies its discovery platform to address similar microbiome issues in production animals. Evolve Biosystems was incorporated in 2011.

Scripps Research is a prominent independent, not-for-profit organization dedicated to advancing biomedical research aimed at enhancing human health. Established from the Scripps Metabolic Clinic in 1924, it has grown into one of the largest institutions of its kind, employing around 3,000 individuals across its campuses in La Jolla, California, and Jupiter, Florida. The institute is recognized for its significant contributions to the biomedical sciences, including the development of new treatments for various diseases such as cancer, rheumatoid arthritis, and hemophilia. Scripps Research is home to renowned scientists, including three Nobel laureates, who engage in cutting-edge research. Additionally, its graduate program in biology and chemistry is highly regarded, consistently ranking among the top ten programs in the United States.

Novartis is a global healthcare company headquartered in Switzerland, dedicated to addressing the evolving needs of patients worldwide through the development and manufacturing of innovative pharmaceuticals. The company focuses on a wide range of therapeutic areas, including oncology, rare diseases, neuroscience, immunology, respiratory, and cardio-metabolic conditions. Novartis is also active in medical nutrition, providing specialized nutritional solutions for individuals with specific dietary needs. Additionally, its animal health division develops advanced medicines aimed at improving the health and welfare of pets, farm animals, and farmed fish. The Genomics Institute of the Novartis Research Foundation plays a crucial role in bridging basic science and preclinical drug discovery, employing nearly 600 scientists to enhance drug development processes. Through its diverse portfolio and commitment to research, Novartis aims to transform patient care and improve health outcomes globally.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company focuses on developing and commercializing innovative silk biomaterial technologies. Its key product, the MIMIX microneedle platform, facilitates the transdermal delivery of vaccines and therapeutics. This sustained release patch technology allows for a controlled release of vaccines, mimicking the natural infection process to enhance immune response and effectiveness. Vaxess's patch is engineered for stability, eliminating the need for refrigeration, which enables shipping and application in low-resource settings. In addition to its vaccine delivery systems, Vaxess is also engaged in creating novel therapies aimed at oncology care and infectious diseases, ultimately striving to improve patient outcomes with reduced treatment burdens.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, that focuses on developing therapeutic products aimed at treating and preventing serious infectious diseases. The company is working on several key therapies, including VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for human immunodeficiency virus, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established collaborations and agreements with various organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, Brii Biosciences, Alnylam Pharmaceuticals, and others, to further its research and development efforts. Additionally, it has a manufacturing agreement with Samsung Biologics for producing antibodies related to COVID-19 treatments. Founded in 2016, Vir Biotechnology aims to leverage its innovative platforms to potentially eradicate diseases like hepatitis B, influenza A, HIV, and tuberculosis.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions that require long-term management. The company is known for its innovative Medici Drug Delivery System, which facilitates subcutaneous delivery of therapies for diseases such as type 2 diabetes, obesity, and autoimmune disorders. Its lead product, ITCA 650, is currently in phase 3 clinical trials designed to provide sustained treatment for diabetes through a steady-state dosing system. Additionally, Intarcia's DUROS platform stabilizes and delivers therapeutic proteins and peptides, including devices aimed at treating conditions such as Hepatitis C. Founded in 1997 and originally named BioMedicines, the company rebranded to Intarcia Therapeutics in 2004. It is headquartered in Boston, Massachusetts, with a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina.

Mologic Ltd. is a UK-based company specializing in the development of diagnostic products primarily for the research market. Founded in 2003 by a father-son team, the company is committed to enhancing patient care and advancing research in various fields, including clinical research, diagnostic development, and wound care. Mologic offers a range of diagnostic tools, such as lateral flow kits for measuring Alpha-1 antitrypsin and desmosine in urine, as well as fMLP assay kits for detecting fMLP in human urine. In addition to its product offerings, the company provides services in assay and reagent development, clinical evaluation studies, and the creation of high-performance antibodies for challenging targets. Mologic aims to make significant contributions to healthcare and education through its innovative research and development efforts.

Univercells is a provider of biomanufacturing solutions focused on making biologics, including vaccines and therapeutics, more accessible and affordable. The company offers innovative technologies designed to reduce manufacturing costs significantly, achieving up to 90% savings on the cost of goods and over 75% in capital investment. Their approach utilizes single-use technologies and integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode. Univercells also provides a range of biomanufacturing services, including scale-X hydro, scale-X carbo, and NevoLine, along with integrated support such as equipment confirmation, facility design, and bioprocess excellence. This comprehensive offering aids cell and gene therapy manufacturers in scaling their operations from research and development to commercial production, ultimately addressing global health challenges.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Masimo Corporation, founded in 1989 and based in Irvine, California, is a medical technology company specializing in non-invasive patient monitoring solutions. The company is renowned for its pulse oximetry technology, notably Masimo Signal Extraction Technology® (SET®), which improves the reliability of blood oxygen measurements, especially in challenging conditions such as patient motion or low perfusion. The technology originated from the founder's observations in neonatal care and has evolved to include a range of advanced monitoring devices and solutions, such as the Root® platform, Masimo Patient SafetyNet™, and the Masimo Stork™ baby monitor. Masimo's product lineup also features noninvasive measurements for various physiological parameters, therapeutic devices like Masimo softFlow™, and wearable health tracking solutions such as the Masimo W1™ watch. The company markets its products directly to healthcare providers and through distributors, as well as collaborating with original equipment manufacturers to integrate its technologies into broader healthcare solutions.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

Just Evotec Biologics, founded in 2014 and acquired by Evotec in 2019, specializes in the development of biotherapeutic technologies aimed at enhancing global access to biotherapeutics. The company focuses on innovative and integrated technologies that streamline the design, development, and manufacturing processes of biologics. Its key strengths lie in antibody discovery, molecular design, and the design of manufacturing processes and facilities. By leveraging scientific expertise and machine learning-driven technologies, Just Evotec Biologics provides clients with comprehensive solutions that accelerate biotherapeutic development while significantly lowering manufacturing costs.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing therapeutics and vaccines using messenger RNA technology. Founded in 2010, the company focuses on various therapeutic areas, including infectious diseases, oncology, rare genetic disorders, and cardiovascular diseases. As of September 2024, Moderna has 40 mRNA development candidates in clinical development, demonstrating its commitment to advancing medical science. The company's mRNA platform has gained significant recognition, particularly with the authorization of its COVID-19 vaccine in December 2020. Moderna has established strategic collaborations with notable organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation. Additionally, it collaborates with Lonza Ltd. and Catalent for the manufacturing of its COVID-19 vaccine. Through its innovative approach, Moderna aims to provide effective solutions for a range of health challenges.

Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health: resistant infectious disease and cancers. Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources. Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.

CureVac is a clinical-stage biopharmaceutical company based in Germany, focused on developing vaccines and therapies utilizing messenger RNA (mRNA). Founded in 2000, the company’s innovative approach involves using mRNA as a data carrier to instruct the body to produce proteins that can combat various diseases. CureVac's pipeline includes novel mRNA-based cancer immunotherapies, prophylactic vaccines for infectious diseases, and molecular therapies aimed at enhancing the body’s production of therapeutic proteins. Its most advanced candidate, CV9104, is currently in Phase IIb clinical trials for prostate cancer treatment. Additionally, CureVac has collaborated with GSK to create second-generation vaccines for seasonal influenza and COVID-19, as well as an avian influenza vaccine, while exploring other mRNA vaccine applications in oncology and various therapeutic areas.

Novavax, Inc. is a late-stage biotechnology company focused on the discovery, development, and commercialization of vaccines aimed at preventing serious infectious diseases. Its lead vaccine candidates include ResVax, designed to protect infants from respiratory syncytial virus (RSV) through maternal immunization, and NanoFlu, targeted at treating seasonal influenza in older adults. Both candidates utilize Novavax's proprietary Matrix-M adjuvant to enhance immune responses. In addition, the company is advancing an RSV F vaccine for older adults and children, and it is developing nanoparticle vaccines against the Ebola virus and a combination respiratory vaccine for influenza and RSV. Novavax is also working on a COVID-19 vaccine, NVX-CoV2373, in collaboration with Takeda Pharmaceutical Company for development and commercialization. Established in 1987 and headquartered in Gaithersburg, Maryland, Novavax utilizes its recombinant technology platform to create highly immunogenic nanoparticles to address urgent global health needs.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

CureVac is a clinical-stage biopharmaceutical company based in Germany, focused on developing vaccines and therapies utilizing messenger RNA (mRNA). Founded in 2000, the company’s innovative approach involves using mRNA as a data carrier to instruct the body to produce proteins that can combat various diseases. CureVac's pipeline includes novel mRNA-based cancer immunotherapies, prophylactic vaccines for infectious diseases, and molecular therapies aimed at enhancing the body’s production of therapeutic proteins. Its most advanced candidate, CV9104, is currently in Phase IIb clinical trials for prostate cancer treatment. Additionally, CureVac has collaborated with GSK to create second-generation vaccines for seasonal influenza and COVID-19, as well as an avian influenza vaccine, while exploring other mRNA vaccine applications in oncology and various therapeutic areas.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

SureChill is a company that has developed an innovative cooling technology capable of maintaining a consistent temperature of 4ºC for extended periods without the need for power, utilizing the unique properties of water. Launched in 2011, its vaccine refrigerators have surpassed the stringent standards set by the World Health Organization, making them invaluable in the medical market. SureChill's technology is instrumental in vaccine preservation, with significant usage by organizations like UNICEF across 46 countries, thereby contributing to global health by ensuring effective vaccine delivery in developing regions. The company has garnered recognition for its impact on the vaccine cold chain, including a $1.5 million grant from the Bill and Melinda Gates Foundation aimed at enhancing this critical infrastructure.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.